{"id":"NCT04902885","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","briefTitle":"Phase 3 Study Evaluating Efficacy, Safety and Pharmacokinetics of Trilaciclib In Small Cell Lung Cancer Patients","officialTitle":"A Randomized, Double-blind, Placebo-controlled, Multi-center Phase 3 Study Evaluating Efficacy, Safety and Pharmacokinetics of Trilaciclib In Extensive-Stage Small Cell Lung Cancer Patients","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-05-25","primaryCompletion":"2021-12-29","completion":"2022-12-31","firstPosted":"2021-05-26","resultsPosted":"2024-07-10","lastUpdate":"2024-07-10"},"enrollment":95,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Extensive-stage Small-cell Lung Cancer"],"interventions":[{"type":"DRUG","name":"Trilaciclib, carboplatin, etoposide，or Topotecan","otherNames":["Trilaciclib plus chemotherapy"]},{"type":"DRUG","name":"placebo, carboplatin, etoposide，or Topotecan","otherNames":["placebo plus chemotherapy"]}],"arms":[{"label":"Part I ( Safety run-in and PK Evaluation); Trilaciclib Group","type":"ACTIVE_COMPARATOR"},{"label":"Part II ( Randomized Double-blind, Placebo-controlled ), Trilaciclib Group","type":"ACTIVE_COMPARATOR"},{"label":"Part II ( Randomized Double-blind, Placebo-controlled ), Placebo Group","type":"PLACEBO_COMPARATOR"}],"summary":"A Randomized, double-blind, placebo-controlled, multi-center Phase 3 study evaluating efficacy, safety and pharmacokinetics of Trilaciclib In Extensive-Stage Small Cell Lung Cancer Patients Receiving Carboplatin combined with Etoposide or Topotecan The study consists of 2 parts: Part 1: safety run-in and pharmacokinetics evaluation of 12 ES-SCLC patients (6 each for first line and second/third line ES-SCLC patients); Part 2: randomized, double-blind, placebo-controlled efficacy confirmation study of 80 ES-SCLC patients (stratified by first line and second/third line ES-SCLC, ECOG PS \\[0-1 vs 2\\] and brain metastases.\n\nThe study includes screening period, treatment period, safety follow-up and survival follow-up.","primaryOutcome":{"measure":"Area Under the Plasma Concentration Versus Time Curve From Time Zero Extrapolated to Infinity(AUC0-inf) for Part 1","timeFrame":"Day1 and Day 3( or Day 5) of Cycle 1 for a 21-day cycle","effectByArm":[{"arm":"Part I ( Safety run-in and PK Evaluation); Trilaciclib Group, First Line ES-SCLC","deltaMin":2200,"sd":14.5},{"arm":"Part I ( Safety run-in and PK Evaluation); Trilaciclib Group, Second or Third Line ES-SCLC","deltaMin":2598,"sd":23.5}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["China"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":12},"commonTop":["White blood cell count decreased","Neutrophil count decreased","Anaemia","Platelet count decreased","Nausea"]}}